Page 59 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Precision medicine and beyond in oncology

epidermal growth factor receptor 2-negative high-risk doi: 10.1038/s41419-023-06302-0
early breast cancer. Breast Cancer (Dove Med Press). 51. Kudo M. Regorafenib as second-line systemic therapy
2024;16:517-527. may change the treatment strategy and management
doi: 10.2147/bctt.S271441 paradigm for hepatocellular carcinoma. Liver Cancer.
2016;5(4):235-244.
42. Goetz MP, Hamilton EP, Campone M, et al. Landscape of
baseline and acquired genomic alterations in circulating doi: 10.1159/000449335
tumor DNA with abemaciclib alone or with endocrine 52. Parvaresh H, Roozitalab G, Golandam F,
therapy in advanced breast cancer. Clin Cancer Res. Behzadi P, Jabbarzadeh Kaboli P. Unraveling the potential
2024;30(10):2233-2244. of ALK-targeted therapies in non-small cell lung cancer:
doi: 10.1158/1078-0432.Ccr-22-3573 Comprehensive insights and future directions. Biomedicines.
2024;12(2):297.
43. Brett JO, Dubash TD, Johnson GN, et al. A gene panel
associated with abemaciclib utility in ESR1-mutated breast doi: 10.3390/biomedicines12020297
cancer after prior cyclin-dependent kinase 4/6-inhibitor 53. Beardslee T, Lawson J. Alectinib and brigatinib: New
progression. JCO Precis Oncol. 2023;7:e2200532. second-generation ALK inhibitors for the treatment of non-
doi: 10.1200/po.22.00532 small cell lung cancer. J Adv Pract Oncol. 2018;9(1):94-101.
44. Cristofanilli M, Rugo HS, Im SA, et al. Overall survival 54. Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of
with palbociclib and fulvestrant in women with HR+/ selpercatinib in RET fusion-positive non-small-cell lung
HER2− ABC: Updated exploratory analyses of PALOMA-3, cancer. N Engl J Med. 2020;383(9):813-824.
a double-blind, phase III randomized study. Clin Cancer Res. doi: 10.1056/NEJMoa2005653
2022;28(16):3433-3442.
55. Wirth LJ, Sherman E, Robinson B, et al. Efficacy of
doi: 10.1158/1078-0432.Ccr-22-0305 selpercatinib in RET-altered thyroid cancers. N Engl J Med.
2020;383(9):825-835.
45. Im SA, Mukai H, Park IH, et al. Palbociclib plus letrozole
as first-line therapy in postmenopausal asian women doi: 10.1056/NEJMoa2005651
with metastatic breast cancer: Results from the phase III, 56. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of
randomized PALOMA-2 study. J Glob Oncol. 2019;5:1-19. larotrectinib in TRK fusion-positive cancers in adults and
doi: 10.1200/jgo.18.00173 children. N Engl J Med. 2018;378(8):731-739.
46. Slamon DJ, Diéras V, Rugo HS, et al. Overall survival with doi: 10.1056/NEJMoa1714448
palbociclib plus letrozole in advanced breast cancer. J Clin 57. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in
Oncol. 2024;42(9):994-1000. patients with advanced or metastatic NTRK fusion-positive
doi: 10.1200/jco.23.00137 solid tumours: Integrated analysis of three phase 1-2 trials.
Lancet Oncol. 2020;21(2):271-282.
47. Harbeck N, Dieras V, Gelmon KA, et al. Effect of palbociclib
plus letrozole on patient-reported health-related quality doi: 10.1016/s1470-2045(19)30691-6
of life: Extended follow-up of the PALOMA-2 trial. ESMO 58. Awasthi R, Maier HJ, Zhang J, Lim S. Kymriah®
Open. 2025;10(4):104497. (tisagenlecleucel) – An overview of the clinical development
doi: 10.1016/j.esmoop.2025.104497 journey of the first approved CAR-T therapy. Hum Vaccin
Immunother. 2023;19(1):2210046.
48. Odogwu L, Mathieu L, Blumenthal G, et al. FDA approval
summary: Dabrafenib and trametinib for the treatment of doi: 10.1080/21645515.2023.2210046
metastatic non‐small cell lung cancers harboring BRAF 59. King AC, Orozco JS. Axicabtagene ciloleucel: The first FDA-
V600E mutations. Oncologist. 2018;23(6):740-745. approved CAR T-cell therapy for relapsed/refractory large
doi: 10.1634/theoncologist.2017-0642 B-cell lymphoma. J Adv Pract Oncol. 2019;10(8):878-882.
49. El-Deiry WS, Goldberg RM, Lenz HJ, et al. The current state doi: 10.6004/jadpro.2019.10.8.9
of molecular testing in the treatment of patients with solid 60. Anderson LD Jr. Idecabtagene vicleucel (ide-cel) CAR T-cell
tumors, 2019. CA Cancer J Clin. 2019;69(4):305-343. therapy for relapsed and refractory multiple myeloma.
Future Oncol. 2022;18(3):277-289.
doi: 10.3322/caac.21560
50. Li Z, Caron de Fromentel C, Kim W, et al. RNA helicase doi: 10.2217/fon-2021-1090
DDX5 modulates sorafenib sensitivity in hepatocellular 61. Sanoyan DA, Seipel K, Bacher U, et al. Real-life experiences
carcinoma via the Wnt/β-catenin-ferroptosis axis. Cell with CAR T-cell therapy with idecabtagene vicleucel (ide-
Death Dis. 2023;14(11):786. cel) for triple-class exposed relapsed/refractory multiple

Volume 8 Issue 3 (2025) 53 doi: 10.36922/ITPS025140018